Nuechterlein, KaitlinAlTurki, AhmedNi, JiayiMartínez Sellés Oliveria Soares, ManuelMartens, PieterRusso, VincenzoNordberg Backelin, Charlotte2022-07-272022-07-272021Nuechterlein, K., AlTurki, A., Ni, J., Martínez-Sellés, M., Martens, P., Russo, V., Backelin, C. N., & Huynh, T. (2021). Real-World Safety of Sacubitril/Valsartan in Women and Men With Heart Failure and Reduced Ejection Fraction: A Meta-analysis. CJC Open, 3(12), S202-S208. https://doi.org/10.1016/j.cjco.2021.09.0092589-790Xhttp://hdl.handle.net/11268/11540Sacubitril/valsartan (SV) is a novel and effective therapy for heart failure with reduced ejection fraction (HFrEF). Despite several sex-specific particularities that may influence drug effects, there has been no prior study evaluating the safety of SV in women with HFrEF in the "real-world." Methods: We performed a literature search to identify observational studies evaluating SV. We contacted all authors to obtain sex-specific data on major adverse outcomes. We compared all-cause and cardiovascular (CV) deaths, heart failure hospitalizations, hyperkalemia, and hypotension in men and women. Results: We identified five cohort studies enrolling 8,981 patients; 6,092 men (67.8%) and 2,889 women (32.2%). The mean age was 67 years in both sexes. The rates for all-cause mortality, CV mortality, heart failure hospitalizations, hypotension, and hyperkalemia were similar between women and men. Although the unadjusted aggregate rates of all-cause and CV mortalities were numerically higher in men than in women, these differences did not reach statistical differences. Conclusion: Our meta-analysis showed similar rates of major adverse events in men and women with HFrEF treated with SV. Larger observational studies with longer duration and a higher number of women are needed to confirm the long-term safety of SV in women in the clinical practice.engValsartánHipertensiónInsuficiencia cardíacajournal article10.1016/j.cjco.2021.09.009open accessEnfermedad cardiovascularTratamiento médico